sales increasing

just announced Gilead sales of ftc and tdf in truvada and atripla increasing to us$700M and us$660M PER QUARTER! in q1 2010

http://www.marketwatch.com/story/antiviral-drugs-help-gilead-post-higher-profit-2010-04-20?reflink=MW_news_stmp

in combo thats $5.6B per year!!!

if avexas atc outperforms 3tc then it will out perform ftc

and atc isnt as bad for the kidneys as tdf
if you use tdf over 2 years you are 5 times more likely to get kidney dysfunction
http://www.hivandhepatitis.com/recent/2010/0209_2010_a.html

on q1 figures tdf alone will bring in almost us$3B for Gilead

how high will atc sales go? whos going to sell it for avexa...and when..???